Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edith A Perez

Showing results (21-30 of 324) with videos related to

Pageof 33
Sort By:
Cancer Control : Journal of the Moffitt Cancer Center|July 16, 2002
Management of Bone Metastases in Advanced Breast CancerEdith A Perez
Breast Cancer Research and Treatment|November 21, 2007
Safety of aromatase inhibitors in the adjuvant settingEdith A Perez
Seminars in Oncology|July 26, 2002
Gemcitabine and targeted therapy in metastatic breast cancerGuangzhi Qu, Edith A Perez
Cancer Treatment Reviews|January 24, 2006
Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancerVivek Roy, Edith A Perez
Cancer Investigation|June 28, 2008
HER2-positive breast cancer: current treatment strategiesEdith A Perez, Mansoina Baweja
Seminars in Oncology|June 27, 2006
New therapies in the treatment of breast cancerVivek Roy, Edith A Perez
Breast Cancer Research and Treatment|December 23, 2008
Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathwaysVivek Roy, Edith A Perez
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2004
Clinical cardiac tolerability of trastuzumabEdith A Perez, Richard Rodeheffer
Oncology (Williston Park, N.Y.)|September 22, 2006
Aromatase inhibitors and bone lossEdith A Perez, Katherine Weilbaecher
Breast Cancer Research : BCR|January 16, 2013
How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?Nadine Norton, Edith A Perez
Pageof 33

Showing results (21-30 of 324) with videos related to

Sort By:
Pageof 33
Cancer Control : Journal of the Moffitt Cancer Center|July 16, 2002
Management of Bone Metastases in Advanced Breast CancerEdith A Perez
Breast Cancer Research and Treatment|November 21, 2007
Safety of aromatase inhibitors in the adjuvant settingEdith A Perez
Seminars in Oncology|July 26, 2002
Gemcitabine and targeted therapy in metastatic breast cancerGuangzhi Qu, Edith A Perez
Cancer Treatment Reviews|January 24, 2006
Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancerVivek Roy, Edith A Perez
Cancer Investigation|June 28, 2008
HER2-positive breast cancer: current treatment strategiesEdith A Perez, Mansoina Baweja
Seminars in Oncology|June 27, 2006
New therapies in the treatment of breast cancerVivek Roy, Edith A Perez
Breast Cancer Research and Treatment|December 23, 2008
Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathwaysVivek Roy, Edith A Perez
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2004
Clinical cardiac tolerability of trastuzumabEdith A Perez, Richard Rodeheffer
Oncology (Williston Park, N.Y.)|September 22, 2006
Aromatase inhibitors and bone lossEdith A Perez, Katherine Weilbaecher
Breast Cancer Research : BCR|January 16, 2013
How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?Nadine Norton, Edith A Perez
Pageof 33